Latest Articles

Publication Date
Rheumatic Heart Disease: Inflammation, Immune Pathways, Valve Remodeling, and the Promise of SGLT2 Inhibitors.

Rheumatic heart disease (RHD) remains the leading cause of acquired valvular heart disease in low- and middle-income countries, affecting an estimated 40 million individuals and disproportionately affecting children and young …

Published: July 16, 2026, midnight
Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may …

Published: July 3, 2026, midnight
SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease.

Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and premature mortality among children and young adults, particularly in low- and middle-income countries. Current management relies on antibiotic …

Published: June 4, 2026, midnight
SGLT2 Inhibitors and Mortality in Endometriosis With Type 2 Diabetes: A Propensity-Matched Analysis.

Endometriosis is increasingly recognized as a systemic inflammatory condition associated with adverse cardiovascular events, yet glucose-lowering drug selection in this population is not evidence-based.

Published: March 18, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!